SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 5.58 |
| Enterprise Value ($M) | 5.57 |
| Book Value ($M) | 0.39 |
| Book Value / Share | 0.00 |
| Price / Book | 14.25 |
| NCAV ($M) | -0.08 |
| NCAV / Share | -0.00 |
| Price / NCAV | -68.86 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.96 |
| Return on Assets (ROA) | -0.78 |
| Return on Equity (ROE) | -0.86 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.08 |
| Current Ratio | 0.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.01 |
| Assets | 0.48 |
| Liabilities | 0.09 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Smith Clarence Edward | 29.49 | 7.47 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| PHCG – Pure Harvest Corporate Group, Inc. | PHGUF – Pharming Group N.V. |
| PHMMF – Pharma Mar, S.A. | PLPL – Plandaí Biotechnology, Inc. |
| PPCB – Propanc Biopharma, Inc. |
Financial data and stock pages provided by
Fintel.io